Accumulating evidence suggests that statin therapy could assist functional recovery following acute ischaemic stroke. A recent study indicates that early administration of statins after intravenous thrombolysis for stroke improves functional outcomes, and reduces mortality and neurological deterioration. Owing to the observational study design, however, these findings should be interpreted cautiously.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roger, V. L. et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 125, 188–197 (2012).
Cappellari, M. et al. The THRombolysis and Statins (THRaST) study. Neurology 80, 655–661 (2013).
Amarenco, P. et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549–559 (2006).
García-Bonilla, L. et al. Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J. Neurochem. 122, 233–243 (2012).
Martinez-Ramirez, S. et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case–control study and a meta-analysis. J. Neurol. 259, 111–118 (2012).
Zhang, L. et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 29, 3486–3494 (2005).
Ní Chróinín, D. et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44, 448–456 (2013).
Chen, J. et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 53, 743–751 (2003).
Montaner, J. et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur. J. Neurol. 15, 82–90 (2008).
Elkind, M. S. et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc. Dis. 28, 266–275 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M. S. Elkind has received research funding from diaDexus, Inc. and BMS-Sanofi for research on inflammatory biomarkers and stroke. He has received personal compensation for serving as a consultant to BMS-Pfizer and Biogen Idec regarding stroke; Jarvik Heart for serving on an Event Adjudication Committee for heart failure trials; Boehringer-Ingelheim for litigation related to Pradaxa; Organon for litigation related to Nuvaring and stroke; and from the American Academy of Neurology for serving as an Editor of the Resident and Fellow Section of the journal Neurology.
Rights and permissions
About this article
Cite this article
Elkind, M. A step closer to statin therapy for stroke?. Nat Rev Neurol 9, 242–244 (2013). https://doi.org/10.1038/nrneurol.2013.58
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.58
